Benactiv gola - irritation and inflammation of the oropharynx - 16 sugar-free orange flavour tablets

Product Description

Benactiv Gola Sugar-Free Lozenges with an orange flavor are used for the treatment of symptoms related to inflammation and/or irritation of the oropharyngeal cavity, also associated with painful sensations.

Indications

Benactiv Gola is a medicine formulated with flurbiprofen, an active ingredient that has an anti-inflammatory and analgesic action in case of inflammation and pain of the throat, mouth and gums.

It can also be used in case of gingivitis, stomatitis, pharyngitis.

Its sugar-free formulation allows it to be taken even by those who cannot or does not want to consume sugars.

Composition

Active ingredient

One lozenge contains: flurbiprofen 8.75 mg.

Excipients

Macrogol 300, potassium hydroxide, orange flavoring, levomenthol, acesulfame K, E110, maltitol syrup, isomaltose.

Dosage and method of use

It is recommended to take one lozenge, to be dissolved slowly in the mouth, every 3 - 6 hours, depending on the need.
Do not exceed the dose of 8 lozenges in 24 hours.

Warnings and precautions

Benactiv Gola Sugar Free Lozenges Orange flavor is a medicine indicated for those patients who need to control their sugar intake. sugars and calories.

Do not administer to children under 12 years of age. Contains the colorant E110, which may cause allergic reactions.

Use of the product, especially if prolonged, may give rise to sensitization or local irritation; in such cases, discontinue treatment and consult your doctor to initiate appropriate therapy, if necessary.
The product should be used with caution in patients with renal, cardiac, or hepatic insufficiency.
It is advisable not to combine the product with other NSAIDs. Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma.

Gastrointestinal Effects
Flurbiprofen should be administered with caution to patients with a history of peptic ulcer and other gastrointestinal diseases, as these conditions may be exacerbated. The risk of gastrointestinal bleeding, ulceration, or perforation is higher with increasing flurbiprofen dosage in patients with a history of ulcers, particularly if complicated with haemorrhage or perforation, and in the elderly. These patients should initiate treatment with the lowest available dose. Gastrointestinal bleeding, ulceration, or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and may occur with or without warning symptoms or with a previous history of serious gastrointestinal events. Patients with a history of gastrointestinal disease, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) early in the course of treatment. Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal.

Undesirable effects may be minimized by using the lowest effective dose for the lowest effective dose. Shortest possible duration of treatment necessary to control symptoms. Do not use for prolonged treatments. After short periods of treatment without appreciable results, consult your doctor. Keep this medicine out of the reach and sight of children.

Contraindications

Flurbiprofen is contraindicated in patients with known hypersensitivity (asthma, urticaria, or allergic-type) to flurbiprofen or to any of the excipients, and to aspirin or other NSAIDs.
Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment.
Flurbiprofen should not be taken by patients with active or a history of ulcerative colitis, Crohn's disease, recurrent peptic ulcer, or gastrointestinal bleeding (defined as two or more distinct episodes of proven ulceration or bleeding).
Flurbiprofen is contraindicated in patients with severe heart failure.

Interactions

Caution should be exercised in patients treated with any of the following drugs, as interactions have been reported in some patients. In any case, inform your doctor if you are taking other medicines.
Aspirin: As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased adverse effects.
Antiplatelet agents: increased risk of gastrointestinal bleeding.
Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding.
Corticosteroids: increased risk of gastrointestinal ulceration or bleeding with NSAIDs.
Cox-2 inhibitors and other NSAIDs: Concomitant use of other NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to potential additive effects.

Undesirable effects

The following undesirable effects have been reported, particularly after administration of systemic formulations:

Blood and lymphatic system disorders

Thrombocytopenia, aplastic anemia and agranulocytosis

Immune system disorders

Anaphylaxis, angioedema, allergic reaction

Nervous system disorders

Dizziness, cerebrovascular accident, visual disturbance, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and somnolence

Acoustic and labyrinth disorders

Tinnitus

Respiratory, thoracic and mediastinal disorders

Respiratory tract reactivity (asthma, bronchospasm and dyspnoea)

Gastrointestinal disorders

The most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease have been reported after administration of flurbiprofen. Less frequently, gastritis, peptic ulcer, perforation, and ulcer haemorrhage have been observed.

Skin and subcutaneous tissue disorders

Skin disorders including rash, pruritus, urticaria, purpura, and very rarely bullous dermatoses (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme).

Renal and urinary tract disorders

Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Topical use of the product, especially if prolonged, may give rise to sensitization or local irritation.

Dissolving the product in tablet form in the oral cavity may cause allergic reactions. may be accompanied by sensations of heat or tingling in the oropharynx. In such cases, treatment should be discontinued and, if necessary, appropriate therapy should be instituted.

Pregnancy and breastfeeding

During the first and second trimester of pregnancy, flurbiprofen should not be administered unless strictly necessary. Administration of flurbiprofen is not recommended in breastfeeding mothers.

Format

16 Orange-Flavour Sugar-Free Lozenges.